

## Phase I clinical development of the 4th generation NSCLC-TKI BBT-176, which targets C797S-harboring EGFR mutations

Bridge Biotherapeutics, Inc.



ONCOLOGY	Phase 1
Product Type	4th generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
Indication	NSCLC (non small cell lung cancer) that targets C797S specific EGFR mutation, obtained after EGRF TKI treatment
Target	Epidermal Growth Factor Receptor (EGFR)
MoA(Mechanism of Action)	BBT-176 is a novel, reversible, broad-spectrum, 4th generation EGFR TKI with high potency against C797S-containing EGFR mutations conferring resistance to Osimertinib or other 3rd generation EGFR TKI
Competitiveness	<ul style="list-style-type: none"> <li>• Osimertinib (AstraZeneca, UK) dominates the global market as a 3rd generation EGFR TKI. There are several Chinese drugs and Lazertinib(developed in Korea) in market as well but their global market share is unknown.</li> <li>• Osimertinib's global market sales reached USD 4.3 billion in 2020, an increase of 36% year on year.</li> <li>• 4th generation EGFR TKI has not yet been commercialized in the world. BBT-176 (Bridge Biotherapeutics) was the earliest to enter clinical trials (April 2, 2021), and BLU-945 (Blueprint Medicines, US) was the next in line to start the clinical trials (June 29, 2021).</li> </ul>
Development Stage	Phase 1
Route of Administration	Oral administration